Our findings reveal that RBM6 promotes the migratory capacity of prostate tumours by inhibiting CDH1, and its activity is also regulated by the key transcription factor ZEB1 of the EMT pathway (Figures 3 and 4). This evidence concerns the gene CDH1 and prostate neoplasm.